Figure 1. Relative risks of vertebral, hip, and nonvertebral fractures (and 95% CIs) in response to the treatments for ... Figure 1. Relative risks of.

Slides:

Advertisements

Similar presentations

Chapter 68 Chapter 68 Fracture Risk Assessment: The Development and Application of FRAX ® Copyright © 2013 Elsevier Inc. All rights reserved.

Advertisements

Downloaded from 1 Alendronate vs. Risedronate Comparison Trial.

Protelos Long-Term Antifracture Efficacy. Protelos Vertebral Antifracture Efficacy over 4 years in SOTI Favors Protelos  RR P

Chapter 83 Chapter 83 Denosumab for the Treatment of Osteoporosis Copyright © 2013 Elsevier Inc. All rights reserved.

Chapter 84 Chapter 84 Strontium Ranelate in the Prevention of Osteoporotic Fractures Copyright © 2013 Elsevier Inc. All rights reserved.

Estrogen plus Progestin, BMD and Fractures: Women’s Health Initiative Jane A. Cauley University of Pittsburgh JAMA 2003; 290 (13) :

Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Peyman Hadji Critical Reviews in Oncology.

Chapter 61: Transplantation Osteoporosis

A. Mean difference in the lumbar spine areal BMD Z-score in published, controlled trials of bisphosphonate therapy for the treatment of children with osteoporosis,

Figure 1. Height distribution for adults with AIS.

Goal-directed Treatment for Osteoporosis

Fig. 1. Trial profile. From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the.

Margaret L. Gourlay, MD, MPH, Robert A. Overman, MPH, Jason P

Deciding on Pharmacological Treatment Post Fracture

Deciding on Pharmacological Treatment Post Fracture

Value in Health Regional Issues

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 Approximate timeline contrasting major historical events in the understanding of ulcerative colitis (red) and ... Figure 1 Approximate timeline.

Figure 1 Flow diagram detailing the systematic review process.

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis

Figure 1 Schematic representation of the experimental design.

Figure 1 Mechanism of mortality benefit associated with radial access

Figure 1: Assessment of basal 10-year risk of fracture with the 2010 tool of the Canadian Association of Radiologists and Osteoporosis Canada. Figure 1:

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

FIGURE 1 PRISMA flow diagram of studies in systematic review

FIGURE 1 Patient enrolment flowchart. SBS, short bowel syndrome.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Source: Figure created by the author based on data ...

bDMARD: biologic DMARD.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

RCTs: randomized controlled ...

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Fig. 1 Flow chart of included patients for analyses

Fig. 1 Flow chart for selection of study subjects

Figure 1. CONSORT flow diagram

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Relationships between pair indices of dance performance (joint entropy or mutual information) and the past ... Figure 1 Relationships between.

FIGURE 1 Consolidated Standards of Reporting Trials (CONSORT) diagram for the follow-up study. Unless provided in the caption above, the following copyright.

Figure 1. Results of search based on the PRISMA statement.14

Figure 1. Trunk and leg fat over study period. LS, log transformed.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

FIGURE 1 Major activities in the working week of a banker

Figure 1. Randomization and dropouts.

FIGURE 1 Weight loss for participants (n = 128) who consumed the high-egg (n = 66) or the low-egg (n = 62) diets ... FIGURE 1 Weight loss for participants.

Fig. 1 A network representation of top 100 co-occurring terms

FIGURE 2 Regression of age- and sex-adjusted mean BMI (A) and WC (B) across obesity (BMI) GRSs. Black dots: age- and ... FIGURE 2 Regression of age- and.

Figure 1 Patient selection.

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Enrollment and outcomes

FIGURE 1 Results for primary meta-analysis of controlled trials for the effects of walnut-enriched compared with ... FIGURE 1 Results for primary meta-analysis.

Figure 1. Mean change in BW (kg) from baseline to end of treatment ± SE in the SUSTAIN 1–3 trials. *P < vs ... Figure 1. Mean change in BW (kg)

Figure 1. Adjusted survival curves for (a) all-cause death, (b) major atherosclerotic events, (c) MI, (d) ischemic ... Figure 1. Adjusted survival curves.

Figure 1: Trade shares of South Korea's major trading partners (% of South Korea's total trade in goods) Figure 1: Trade shares of South Korea's major.

Figure 1. Kaplan Meier curves showing crude product limit survival estimates and 95% confidence intervals for time to ... Figure 1. Kaplan Meier curves.

Figure 1. Consolidated Standards of Reporting Trials (or CONSORT) diagram for the current study. Unless provided in the caption above, the following copyright.

Figure 1. Measuring respondent unhappiness with their child marrying someone from the other party and happiness with ... Figure 1. Measuring respondent.

Figure 1 ABCDE of primary prevention.2

Figure 1. (A) Composite renal outcome, (B) worsening kidney function, and (C) incident albuminuria by fasting glucose ... Figure 1. (A) Composite renal.

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Figure 1. Evolutionary process of a policy field.

Figure 1. Overall response rates in wild-type versus RAS and RAS/BRAF mutations detected by nanofluidic digital PCR ... Figure 1. Overall response rates.

Subjects Randomized to Denosumab or Bisphosphonate Therapy

Presentation transcript:

Figure 1. Relative risks of vertebral, hip, and nonvertebral fractures (and 95% CIs) in response to the treatments for ... Figure 1. Relative risks of vertebral, hip, and nonvertebral fractures (and 95% CIs) in response to the treatments for postmenopausal osteoporosis, calculated directly and compared with placebo. Note that the evidence is based on a direct meta-analysis of 107 trials of drugs in postmenopausal women with primary osteoporosis in which the trial duration lasted for 3 to 120 mo. In this analysis, each agent was compared with placebo and so direct comparisons should not be made between treatments based on this figure. (12). [Adapted with permission from data presented in Moreno PB, Kapoor E, Asi N, et al. Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 2019;104(5):1623-1630]. Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © 2019 Endocrine Society None, Volume 104, Issue 5, 25 March 2019, Pages 1595–1622, https://doi.org/10.1210/jc.2019-00221 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 2. Algorithm for the management of postmenopausal osteoporosis Figure 2. Algorithm for the management of postmenopausal osteoporosis. Note that in this algorithm, we considered that ... Figure 2. Algorithm for the management of postmenopausal osteoporosis. Note that in this algorithm, we considered that a determination of fracture risk would include measurement of lumbar spine and hip BMD and inserting the total hip or femoral neck BMD value into the FRAX tool. Using that FRAX algorithm, we define the following risk categories: “low risk” includes no prior hip or spine fractures, a BMD T-score at the hip and spine both above −1.0, and 10-year hip fracture risk <3% and 10-year risk of major osteoporotic fractures <20%; “moderate risk” includes no prior hip or spine fractures, a BMD T-score at the hip and spine both above −2.5, or 10-year hip fracture risk <3% or risk of major osteoporotic fractures <20%; “high risk” includes a prior spine or hip fracture, or a BMD T-score at the hip or spine of −2.5 or below, or 10-year hip fracture risk ≥3%, or risk of major osteoporotic fracture risk ≥20%; and “very high risk” includes multiple spine fractures and a BMD T-score at the hip or spine of −2.5 or below. Unless provided in the caption above, the following copyright applies to the content of this slide: Copyright © 2019 Endocrine Society None, Volume 104, Issue 5, 25 March 2019, Pages 1595–1622, https://doi.org/10.1210/jc.2019-00221 The content of this slide may be subject to copyright: please see the slide notes for details.